0001323885-26-000018
SEC filingAtriCure reported Q1 2026 worldwide revenue of $141.2 million, up 14.3% year-over-year, with net income of $0.1 million and issued full-year 2026 guidance of $600-610 million revenue.
AtriCure's Q1 2026 results demonstrated robust revenue growth of 14.3% to $141.2 million, with U.S. sales accelerating to 14.9% driven by strong performance in cryoSPHERE MAX probe for post-operative pain management, AtriClip FLEX-Mini and PRO-Mini for appendage management, and EnCompass clamp in open ablation. International revenue grew 11.5%, supported by direct markets in appendage management, open ablation, and pain management. Gross margin improved to 77.4% from favorable product and geographic mix, contributing to operational income of $0.5 million versus a prior-year loss. Adjusted EBITDA surged 95% to $17.1 million, reflecting enhanced profitability. CEO Michael Carrel highlighted the durability of the growth model through disciplined execution and product adoption, positioning the company for sustained value creation. Balance sheet remains solid with $146.2 million in cash equivalents and reduced current liabilities. Full-year guidance of $600-610 million revenue and $80-82 million Adjusted EBITDA signals confidence in continued momentum amid ongoing clinical initiatives.